Literature DB >> 7889317

Variant subpopulations of Staphylococcus aureus as cause of persistent and recurrent infections.

R A Proctor1, J M Balwit, O Vesga.   

Abstract

While S. aureus small colony variants (SCVs) have been recognized in clinical materials for decades, only recently have these strains been linked to persistent, resistant, and relapsing infections. The biochemical basis for this phenotype appears to be reduced electron transport, which leads to many changes in these organisms, including decreased alpha-toxin production. Reduced alpha-toxin has been found to facilitate bacterial survival within cultured endothelial cells. This SCV subpopulation is more resistant to antibiotics, grows very slowly, and demonstrates unusual colony morphology. Hence, these resistant strains can be easily overloaded in the clinical microbiology laboratory, and may be resistant to conventional antibiotic therapy. Clinicians should ask the laboratory to search for SCVs with relapsing and resistant S. aureus infections.

Entities:  

Mesh:

Year:  1994        PMID: 7889317

Source DB:  PubMed          Journal:  Infect Agents Dis        ISSN: 1056-2044


  45 in total

1.  Staphylococcus aureus, Platelets, and the Heart.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-08       Impact factor: 3.725

2.  Contribution of Catalase and Superoxide Dismutase to the Intracellular Survival of Clinical Isolates of Staphylococcus aureus in Murine Macrophages.

Authors:  Debaditya Das; Biswadev Bishayi
Journal:  Indian J Microbiol       Date:  2011-01-25       Impact factor: 2.461

3.  sigmaB activity in a Staphylococcus aureus hemB mutant.

Authors:  Maria M Senn; Markus Bischoff; Christof von Eiff; Brigitte Berger-Bächi
Journal:  J Bacteriol       Date:  2005-11       Impact factor: 3.490

4.  Enhanced post-stationary-phase survival of a clinical thymidine-dependent small-colony variant of Staphylococcus aureus results from lack of a functional tricarboxylic acid cycle.

Authors:  Indranil Chatterjee; Mathias Herrmann; Richard A Proctor; Georg Peters; Barbara C Kahl
Journal:  J Bacteriol       Date:  2007-01-26       Impact factor: 3.490

5.  Clinical characteristics associated with isolation of small-colony variants of Staphylococcus aureus and Pseudomonas aeruginosa from respiratory secretions of patients with cystic fibrosis.

Authors:  Michael Schneider; Kathrin Mühlemann; Sara Droz; Sabine Couzinet; Carmen Casaulta; Stefan Zimmerli
Journal:  J Clin Microbiol       Date:  2008-03-05       Impact factor: 5.948

6.  A Comparison between Two Pathophysiologically Different yet Microbiologically Similar Lung Diseases: Cystic Fibrosis and Chronic Obstructive Pulmonary Disease.

Authors:  Daniel E Fenker; Cameron T McDaniel; Warunya Panmanee; Ralph J Panos; Eric J Sorscher; Carleen Sabusap; John P Clancy; Daniel J Hassett
Journal:  Int J Respir Pulm Med       Date:  2018-11-29

7.  Identification of point mutations in clinical Staphylococcus aureus strains that produce small-colony variants auxotrophic for menadione.

Authors:  Melissa A Dean; Randall J Olsen; S Wesley Long; Adriana E Rosato; James M Musser
Journal:  Infect Immun       Date:  2014-01-22       Impact factor: 3.441

8.  Artificial Selection for Pathogenicity Mutations in Staphylococcus aureus Identifies Novel Factors Relevant to Chronic Infection.

Authors:  Kathryn McLean; Elizabeth A Holmes; Kelsi Penewit; Duankun K Lee; Samantha R Hardy; Mingxin Ren; Maxwell P Krist; Kevin Huang; Adam Waalkes; Stephen J Salipante
Journal:  Infect Immun       Date:  2019-03-25       Impact factor: 3.441

9.  Two diarylurea electron transport inhibitors reduce Staphylococcus aureus hemolytic activity and protect cultured endothelial cells from lysis.

Authors:  R A Proctor; S C Dalal; B Kahl; D Brar; G Peters; W W Nichols
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

10.  Staphylocidal action of thrombin-induced platelet microbicidal protein is not solely dependent on transmembrane potential.

Authors:  S P Koo; A S Bayer; H G Sahl; R A Proctor; M R Yeaman
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.